NiKang Therapeutics has administered the initial dose to a patient in its Phase 1/1b trial of NKT3447, an oral drug targeting CDK2 that decreases Cyclin E levels.

On April 5, 2024, the latest clinical findings of IMM27M were unveiled at the 2024 AACR, demonstrating its potential effect and setting the stage for subsequent investigations.

Both the GMP (Good Manufacturing Practice) systems in China and the United States aim to ensure quality control and safety in pharmaceutical production.

On April 5, 2024, the first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study) was reported in 2024 AACR.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.

On April 7, 2024, the latest clinical data of Cadonilimab (the PD-1/CTLA-4 bispecific antibody) plus chemo were reported in 2024 AACR.

Fresenius has declared through its subsidiary, Fresenius Kabi, the launch of Tyenne (tocilizumab-aazg) in the United States.

On April 5, 2024, the latest clinical trial of Atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk LA SCCHN were reported in 2024 AACR.

The "Berlin Patient" refers to Timothy Ray Brown, an American man who was known as the first person to be cured of HIV/AIDS.

On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.

Recurrence-free survival (RFS) is a clinical endpoint used in oncology to measure the effectiveness of cancer treatments.

April 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.